Peptides

Peptides

We’re Ready. MediVera Compounding Pharmacy™ has completed internal and third-party testing on six new peptides. Launch is set to follow final approval.

Peptide therapy is one of the most actively evolving categories in compounding pharmacy, and the regulatory framework is moving alongside it. At MediVera, we’ve been closely tracking the FDA’s review process, building the operational and pharmacist infrastructure necessary to compound peptides in accordance with PCAB-accredited standards, in ISO-7 cleanrooms, and with third-party testing on every sterile batch.

Our planned peptide program spans four therapeutic categories: growth hormone and performance, healing and recovery, cognitive and nootropic, and longevity and immune support. Compounds within each category will be available across injectable, oral, nasal, and topical routes, depending on the formulation.

The availability of each compound depends on its individual regulatory pathway, and timelines vary accordingly. Join the waitlist below to be notified, compound by compound, as each becomes available through MediVera, whether you’re a licensed prescriber building a peptide protocol for your practice or a telehealth platform evaluating fulfillment partners for a peptide program.

MediVera compounds additional peptide-based medications outside this program, including GLP-1 medications for weight management and glutathione for longevity support. View our Weight Management and Longevity pages for current offerings.